A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics (PK) of MK-8189 in participants
with moderate hepatic impairment (based on the Child-Pugh classification) to healthy
participants. This is Part 1 of the study; following review of the safety and PK data from
Part 1, a decision will be made as to whether Part 2 of the study will be initiated. If done,
Part 2 of the study will compare the PK of MK-8189 in participants with mild hepatic
impairment to healthy participants.